StocksMedium•5 November 2026•
1 min read
Arcutis Biotherapeutics Shares Fall After Q3 Earnings Miss Expectations
Key Facts
1Arcutis Biotherapeutics reported Q3 earnings of $0.06 per share, missing the consensus estimate of $0.17 per share.
2ZORYVE net product revenue reached $143.9 million for the third quarter of 2026.
Arcutis Biotherapeutics reported third-quarter earnings of $0.06 per share, missing the consensus analyst estimate of $0.17 per share. Seeking Alpha reported that the company's stock declined following the announcement as higher expenses offset revenue gains.
Net product revenue for ZORYVE reached $143.9 million for the third quarter of 2026, driving a 45% year-over-year increase in total revenue. The earnings miss overshadowed the top-line growth and an upward revision of full-year sales guidance, pressuring the stock during the November 5, 2026, session.